Results 71 to 80 of about 14,440 (242)

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Daniel Himelstein, Megan McNicol, Mahmoud Abdel‐Rasoul, Brendan M. Boyle, Hilary K. Michel, Ross Maltz   +5 more
wiley   +1 more source

Endoscopic findings in patients with Shwachman–Diamond syndrome: A report from the North American Shwachman–Diamond syndrome registry

JPGN Reports, EarlyView.
Abstract Objectives Shwachman–Diamond syndrome (SDS) is an inherited bone marrow failure disorder, and its endoscopic phenotype is poorly defined. We sought to characterize endoscopic findings in patients with genetically confirmed SDS. Methods Retrospective registry study of 45 patients with biallelic Shwachman–Bodian–Diamond syndrome mutations and ...
Elizabeth Korn, Jane Koo, Diana Schwarz, Meghan Haney, Juan Putra, Jaeson Kim, Leah Cheng, Sarah Steltz, Lois Schwarz, Sara Loveless, Richard Cooper, Claire Dusa, Kasiani C. Myers, Akiko Shimamura, Andrew Wehrman, Amit S. Grover   +15 more
wiley   +1 more source

Treatment success in cats with chronic enteropathy is associated with a decrease in fecal calprotectin concentrations

Frontiers in Veterinary Science
Feline chronic enteropathies (FCE) are challenging to diagnose and monitor for progression and response to treatment. Fecal calprotectin might be a useful non-invasive marker to evaluate clinical endpoints of therapeutic monitoring in FCE.
Romy M. Heilmann, Denise S. Riggers, Isla Trewin, Gábor Köller, Aarti Kathrani   +4 more
doaj   +1 more source

Knowledge and practice regarding eosinophilic gastrointestinal disorders other than eosinophilic esophagitis among pediatric gastroenterologists of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

JPGN Reports, EarlyView.
Abstract Objective Evaluating clinical practices in the management of non‐esophageal eosinophilic gastrointestinal disorders (non‐EoE EGIDs) among pediatric gastroenterologists in Latin America. Methods A cross‐sectional descriptive study was conducted using a survey distributed via the REDCap platform.
Sofia Paz, Michelle Higuera Carrillo, Alonso Rafael Echavez Agudelo, Mário Cesar Vieira, Juan Pablo Riveros López, Natali González Rozó, Gustavo Javier Tagliaferro, Fabiola Sánchez Hernández, Catalina Ortiz Piedrahita, Wilson Daza Carreño, Ailim Margarita Carias Domínguez, José Fernando Vera Chamorro, Sabine Krüger Truppel, Maximiliano Fernández Rivas, César Augusto Moreno Serrano, Pablo Torres Córdova, Carlos Marcelo Timossi, Pablo Vásquez   +17 more
wiley   +1 more source

Serum and Fecal Calprotectin Levels Do Not Alter Significantly in Patients With Psoriasis Switching to Brodalumab After Loss of Effect From TNF‐α Inhibitors

JEADV Clinical Practice
Background Psoriasis is a chronic inflammatory skin disease often associated with systemic conditions like psoriatic arthritis and inflammatory bowel disease (IBD).
Admir Vižlin, Hans‐Peter Claesson, Ylva Andersch Björkman, Martin Gillstedt, Eva Klingberg, Emanuela Micu, Amra Osmančević   +6 more
doaj   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Value of fecal calprotectin in the diagnosis of chronic inflammatory bowel diseases in children

Zdorovʹe Rebenka, 2018
Background. Inflammatory bowel diseases are considered to be one of the most difficult problems of children gastroenterology, which have not only medical but also social significance.
T.V. Yaroshevska, K.V. Skriabina, N.B. Sapa   +2 more
doaj   +1 more source

Fecal calprotectin in the differential diagnosis of acute intestinal infections [PDF]

, 2018
Infectious diarrhea takes a leading position in all infectious diseases  worldwide. As a result of the pathogens diversity, patient-specific  diagnosis and treatments are needed. Additional laboratory tests are crucial for differentiation among pathogens,
E. D. Vlkova, M. D. Gospodinova, I. T. Todorov   +2 more
core   +2 more sources

Fecal Calprotectin Associated with Spondyloarthritis Disease Activity [PDF]

, 2020
Background: Fecal calprotectin (FC) is one of fecal biomarkers that has validation to distinguish the organic and functional bowel disease but the relationship with disease activity in Spondyloarthritis (SpA) is still questionable.
Astu Anindya Jati, Ummi Maimunah, Yuliasih, Iswan Abbas Nusi   +3 more
core   +3 more sources

Comparative Real‐World Effectiveness of Anti‐TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA‐IBD Registry in Germany

Alimentary Pharmacology &Therapeutics, EarlyView.
A pooled analysis from the prospective UMBRELLA‐IBD registry in Germany (n = 1567) showed comparative real‐world effectiveness in treatment persistence and clinical remission of anti‐TNF, Ustekinumab and Vedolizumab in Crohn's disease patients over 24 months.
Arne Bokemeyer, Florian Tran, Sandra Plachta‐Danielzik, Elena Gilman, Thomas Wenske, Matthew Gaskins, Stefan Schreiber, Bernd Bokemeyer   +7 more
wiley   +1 more source